Arcadia Biosciences Receives Nasdaq Notice for Low Stockholders' Equity

What Happened
Arcadia Biosciences, Inc. announced in an 8-K that on August 31, 2026 it received a letter from Nasdaq’s Listing Qualifications Department notifying the company that it no longer met Nasdaq Capital Market’s minimum stockholders’ equity requirement. The company reported stockholders’ equity of $633,000 in its June 30, 2026 Form 10-Q, below the $2,500,000 threshold in Nasdaq Listing Rule 5550(b)(1). The letter confirmed the company also did not meet alternative standards (market value of listed securities or net income).

Key Details

• Nasdaq letter dated August 31, 2026; company reported $633,000 stockholders’ equity as of June 30, 2026.
• Required minimum under Nasdaq Listing Rule 5550(b)(1): $2,500,000.
• Arcadia has 45 calendar days (until October 15, 2026) to submit a plan to regain compliance; if accepted, Nasdaq may grant up to a 180-day extension to evidence compliance.
• If Nasdaq rejects any plan, the company can appeal to a Nasdaq Hearings Panel, which typically stays delisting pending a decision. The company said it intends to submit a plan and is evaluating alternatives.

Why It Matters
This notice does not immediately delist Arcadia’s stock, but it is a material risk to continued Nasdaq listing and could affect investor confidence and the company’s ability to raise capital. Investors should monitor the company’s submission to Nasdaq, any acceptance/extensions granted, and subsequent filings for updates on whether Arcadia regains compliance or pursues an appeal.